Fine chemicals group Siegfried (Zofingen, Switzerland) says in the past few months pharmaceutical companies have begun to show an increasing interest in undertaking exclusive synthesis projects at the company. “The reason for this interest is seen in the comprehensive restructuring programs launched by about two-thirds of the large, globally active pharma companies, resulting in the elimination of excess chemical capacity,” Siegfried says. That perceived change in the market has already led to an increase in exclusive synthesis activity at Siegfried...